Grössmann, N. (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.

Fischer, S. and Novelli, A. (2016): Re-orientation of the Austrian parent-child preventive care programme. Part XII: Economic evaluation of selected screenings during pregnancy. HTA-Projektbericht 91.

Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.

Rummel, P. and Hawlik, K. and Wild, C. (2016): Health Technology Assessments on Medical Devices in Europe. Rapid Assessment 012.

Fischer, S. and Tüchler, H. and Piso, B. (2016): Outpatient cardiac rehabilitation part VII: Economic Evaluation. HTA-Projektbericht 89.

Winkler, R. and Rosian, K. (2016): Supply Mandates. HTA-Projektbericht 88.

Ettinger, S. and Stanak, M. and Huić, M. and Hacek, R.T. and Ercevic, D. and Grenkovic, R. and Wild, C. (2016): Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk.. Decision Support Document 103.

Emprechtinger, R. and Fischer, S. and Wild, C. (2016): Options to identify inappropriate use of MRI, Part 3. HTA-Projektbericht 80c.

Mantsch, S. and Petersen, P. and Wild, C. (2016): Pharma: Disclosure of payments in Austria 2015. Rapid Assessment 007d.

Kisser, A. (2016): Hepatitis C virus screening in hospitals. Decision Support Document 102.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 28th Prioritisation – 3rd quarter 2016. HSO: 28th Prioritisation.

McGahan, L. (2016): Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. DSD: Horizon Scanning in Oncology 61.

Grössmann, N. (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.

Piso, B. and Tüchler, H. (2016): Outpatient cardiac rehabilitation part VI: prospective multi-centre cohort study (comparing patients with and without phase III). HTA-Projektbericht 90.

Grössmann, N. (2016): Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. DSD: Horizon Scanning in Oncology 59.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 27th Prioritisation – 2nd quarter 2016 . HSO: 27th Prioritisation.

Grössmann, N. (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.

Fried, A. and Wild, C. (2016): Involvement of Citizens and Patients in HTA-Processes – International Experiences and Good Practice Examples. HTA-Projektbericht 86.

Salamon, Maria (2016): Screening, diagnostics and indication for occupational therapy in children and adolescents with Developmental Coordination Disorders. Decision Support Document 96.

Emprechtinger, R. and Erdos, J. and Piso, B. (2016): Thrombectomy for ischaemic stroke: Patient characteristics, structural requirements and (differential) diagnostics. HTA-Projektbericht 87.

Semlitsch, T. and Horvath, K. (2016): Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB). 2nd Update 2016 . Decision Support Document 24/ 2. Update 2016.

Kisser, A. and Emprechtinger, R. (2016): Leadless pacemakers for right ventricle pacing. Decision Support Document 97.

Fischer, S. (2016): Single-step scaffold-based cartilage repair in the knee. Decision Support Document 98.

Schiller-Frühwirth, I. and Kisser, A. (2016): Upper airway stimulation for moderate-to-severe sleep apnea. Decision Support Document 100.

Piso, B. and Reinsperger, I. and Rosian, K. (2016): Radiofrequency denervation for sacroiliac and facet joint pain. Decision Support Document 99.

Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.

Erdos, J. and Stanak, M. (2016): Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD). Decision Support Document 101.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 26th Prioritisation – 1st quarter 2016. HSO: 26th Prioritisation.

Grössmann, N. and Baumann, M. (2016): Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 57.

Baumann, M. and Grössmann, N. (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.

Rothschedl, E. and Nachtnebel, A. (2016): Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. DSD: Horizon Scanning in Oncology 56.

Wild, C. and Blagojevic, S. (2016): Annual Report 2015.

Wild, C. and Emprechtinger, R. (2016): Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. National Report: German Summary of the correspondent EUnetHTA Report. Decision Support Document 94.

Gregor-Patera, N. and Schader , M. and Wild, C. (2016): Non-interventional studies (NIS) in Austria. A systematic analysis. Rapid Assessment 007c.